SystImmune Inc.

SystImmune Inc. is a biopharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and multi-specific antibodies, as well as antibody-drug conjugates (ADCs). Our objective is to create biologics that work through systematic intervention on solid tumor microenvironment, to either directly attack the tumor and/or to activate the immune system to attack the tumor. We are a group of highly experienced immuno-oncology scientists utilizing several technology platforms to develop world class advanced antibody-based drug therapies. SystImmune Inc., is a wholly owned and subsidiary of a pharmaceutical company and funded by venture capital firm OrbiMed. We are willing to seek parties interested in working with as partners to develop, commercialize, and bring our novel therapeutics to patients around the world.